Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Aralez Pharmaceuticals clinical trials
The registry lists 27 studies whose lead sponsor is Aralez Pharmaceuticals or one of 1 company grouped under it. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Feb 18, 2016.
Registry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Aralez Pharmaceuticals.
Studies
Recruiting first, then most recently updated. Showing 27 of 27.
- A Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated UlcersCompletedNCT00961350Phase 3
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated UlcersCompletedNCT00960869Phase 3
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- Study to Evaluate the Long-Term Safety of PA32540 in Subjects Who Are at Risk for Developing Aspirin-Associated Gastric UlcersCompletedNCT00995410Phase 3
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- Study of Lornoxicam or Ketorolac or Placebo for Post-Operative Pain After BunionectomyCompletedNCT00293631Phase 2
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- Study of Lornoxicam or Placebo for Acute Treatment of the Headache of Migraine.CompletedNCT00293657Phase 2
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- A Study to Evaluate Platlet Aggregation of Clopidogrel, EC Aspirin 81 mg, EC Omeprazole 40 mg Compare to PA32540CompletedNCT01557335Phase 1
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With OsteoarthritisCompletedNCT00664560Phase 3
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With OsteoarthritisCompletedNCT00665431Phase 3
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) NaproxenCompletedNCT00527787Phase 3
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) NaproxenCompletedNCT01129011Phase 3
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers in High Risk Subjects Compared to ArthrotecTerminatedNCT00594854Phase 3
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- A 12-month, Phase 3, Open-label, Multi-center Study to Evaluate the Long-term Safety of PN400 (VIMOVO)CompletedNCT00527904Phase 3
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- Phase I Study to Evaluate Bioavailability of Overencapsulated CelecoxibCompletedNCT00729495Phase 1
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- A Parallel Group Study to Compare the Gastroprotective Effects of PA 325 Versus 81 mg Enteric Coated AspirinCompletedNCT00441519Phase 1
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- Study Evaluating the Effect on Gastroduodenal Mucosa of PA32540, PA32540 and Celecoxib, and Aspirin With CelecoxibCompletedNCT00700687Phase 1
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- A Pharmacokinetic (PK) Study Evaluating Naproxen and Esomeprazole Plasma LevelsCompletedNCT00749385Phase 1
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- Study Evaluating the Bioavailability of Naproxen 375 mg in Two FormulationsCompletedNCT00692055Phase 1
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- Study Evaluating the Effect of Food on the Bioavailability of PN400 ComponentsCompletedNCT00676442Phase 1
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- Study Evaluating the Bioavailability of Naproxen 500 mg in Three FormulationsCompletedNCT00665743Phase 1
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- PK Study to Evaluate Esomeprazole Plasma Levels Following Administration of PN 400CompletedNCT00599404Phase 1
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- An Open-Label, Randomized, Comparative 3-Way Cross-Over Study to Evaluate the Effect of Food on the 24-Hour Intragastric pH at Day 5 After Twice Daily Oral Administration of PN 200 (Omeprazole/Naproxen) in Healthy VolunteersCompletedNCT00442208Phase 1
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PN 200 or Naproxen in Subjects Who Are at Risk for Developing NSAID-Associated Ulcers.CompletedNCT00367211Phase 3
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- Evaluate Relative Bioavailability of PA32540 (Asa/Omeprazole), Its Aspirin Component, and Ecotrin® in Healthy VolunteersCompletedNCT00632086Phase 1
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- To Compare the Gastroprotective Effects and Pharmacokinetic Profile of PA Versus Enteric-Coated AspirinCompletedNCT00442052Phase 1
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- The Safety Of Combo Formulation In The Treatment Of Multiple Episodes Of Acute Migraine Over 12 MonthsCompletedNCT00442221Phase 3
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- To Evaluate the Safety and Efficacy of Trexima in the Acute Treatment of Migraine HeadachesCompletedNCT00433732Phase 3
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals
- To Evaluate the Safety and Efficacy of Trexima in the Acute Treatment of Migrane HeadachesCompletedNCT00434083Phase 3
Sponsor listed in the registry: POZEN · First submitted before POZEN became part of Aralez Pharmaceuticals